Efficacy of human epidermal growth factor combined with medical radiation protective spray in the treatment of radiodermatitis in breast cancer patients
CAO Lei
CONG Li
WU Xin
Abstract：Objective To investigate the clinical efficacy of human epidermal growth factor(EGF)combined with medical radiation protective spray in the treatment of radiodermatitis following breast-conserving surgery for breast cancer.Methods A total of 80 breast cancer patients who developed radiodermatitis during radiotherapy after breast-conserving surgery at Jiangsu Province(Suqian)Hospital(Suqian First Hospital)between June 2021 and December 2023 were includ-ed in this retrospective analysis.Based on the actual medication regimen received,patients were divided into the growth factor group(36 cases)and the conventional treatment group(44 cases).The conventional treatment group received stan-dard adjuvant radiotherapy combined with medical radiation protective spray,while the growth factor group received the conventional treatment group's regimen plus topical human EGF.Both groups were treated continuously for 6 weeks.The total effective rate,Radiation Skin Injury Assessment Scale(RSIAS)scores,Karnofsky Performance Status(KPS)scores,levels of interleukin-6(IL-6)and serum EGF,and treatment interruption time were compared between the two groups.Results The total effective rate in the growth factor group was 86.11%(31/36),significantly higher than that in the conven-tional treatment group(47.73%(21/44)),with a statistically significant difference(χ2=12.823,P＜0.05).After treatment,the RSIAS score in the growth factor group((4.20±1.50)points)was lower than that in the conventional treatment group((6.10±2.20)points),and both groups were significant lower than pre-treatment levels(the growth factor group:(10.66±2.65)points;the conventional treatment group:(10.57±2.21)points),with statistically significant differences(t=4.409,12.729,9.508,all P＜0.05).The KPS score in the growth factor group((83.41±6.20)points)was higher than that in the conventional treatment group((78.50±5.98)points),and both groups were higher than pre-treatment levels(the growth factor group:(69.50±2.66)points;the conventional treatment group:(68.32±3.98)points),with statistically significant differences(t=3.594,12.371,9.400,all P＜0.05).The IL-6 level in the growth factor group((1.91±0.26)ng/L)was lower than that in the conventional treatment group((2.13±0.27)ng/L),and both groups were lower than pre-treatment levels(the growth factor group:(3.53±0.47)ng/L;the con-ventional treatment group:(3.41±0.67)ng/L),with statistically significant differences(t=3.686,18.096,11.754,all P＜0.05).The serum EGF level in the growth factor group((1 458.26±39.26)pg/mL)was higher than that in the conventional treatment group((1 277.96±34.54)pg/mL),and both groups were higher than pre-treatment levels(the growth factor group:(809.23±34.75)pg/mL;the conventional treatment group:(808.66±39.01)pg/mL),with statistically significant differences(t=21.841,74.274,59.746,all P＜0.05).The treatment interruption time in the growth factor group((3.53±0.38)days)was shorter than that in the conventional treatment group((5.41±0.88)days),and the difference was statistically significant(t=11.930,P＜0.05).Conclusion The combination of human EGF and medical radiation protective spray can effectively improve the therapeutic outcome for radiodermatitis after breast-conserving surgery in breast cancer patients,regulate inflammatory factor levels,pro-mote skin repair,and improve patients'quality of life.
Keywords：human epidermal growth factormedical radiation protection spraybreast cancerradiodermatitisinflam-matory factor
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1546-1550 )